{"filing":{"accession_number":"0001213900-26-098090","cik":"0001837821","ticker":"ZJYL","company_name":"Jin Medical International Ltd.","form":"6-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"ea0304810-6k_jinmed.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1837821/000121390026098090/ea0304810-6k_jinmed.htm"},"events":[{"id":32073,"run_id":29462,"accession_number":"0001213900-26-098090","anchor_item_number":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"The 6-K discloses entry into a VIE Control Master Acquisition Agreement on September 8, 2026, whereby Jin Medical International will obtain contractual control over Huaxia Qiying (the Target) through VIE arrangements with Chenglan Kangxu and related parties. The transaction involves aggregate consideration of US$159.4 million and issuance of 71.3 million Class A ordinary shares, plus ancillary asset and equity transfers. This constitutes a material acquisition activity under Item 1.01 of Form 8-K (or its 6-K equivalent), with substantial financial and operational implications for the registrant's expansion into ginseng-related biological assets and senior-health platform development.","company_name":"Jin Medical International Ltd.","ticker":"ZJYL","filing_date":"2026-09-08","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":35151,"accession_number":"0001213900-26-098090","item_number":null,"item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The 6-K discloses entry into a VIE Control Master Acquisition Agreement on September 8, 2026, whereby Jin Medical International will obtain contractual control over Huaxia Qiying (the Target) through VIE arrangements with Chenglan Kangxu and related parties. The transaction involves aggregate consideration of US$159.4 million and issuance of 71.3 million Class A ordinary shares, plus ancillary asset and equity transfers. This constitutes a material acquisition activity under Item 1.01 of Form 8-K (or its 6-K equivalent), with substantial financial and operational implications for the registrant's expansion into ginseng-related biological assets and senior-health platform development.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T21:06:38.908847+00:00","company_name":"Jin Medical International Ltd.","ticker":"ZJYL","filing_date":"2026-09-08"}]}